000
| 02067nam 2200361zi 4500 |
---|
001 | 9.874552 |
---|
003 | CaOODSP |
---|
005 | 20240823090126 |
---|
006 | m o d f |
---|
007 | cr ||||||||||| |
---|
008 | 190820e201906##onc o f000 0 eng d |
---|
020 | |a9780660312880 |
---|
040 | |aCaOODSP|beng|erda|cCaOODSP |
---|
043 | |an-cn--- |
---|
086 | 1 |aH164-273/2019E-1-PDF |
---|
245 | 00|aGuidance document : |bregulatory requirements for drug identification numbers (DINs). |
---|
250 | |a[2019/06/19 edition]. |
---|
264 | 1|a[Ottawa] : |bHealth Canada = Santé Canada, |cJune 2019. |
---|
264 | 4|c©2019 |
---|
300 | |a1 online resource (28 pages) |
---|
336 | |atext|btxt|2rdacontent |
---|
337 | |acomputer|bc|2rdamedia |
---|
338 | |aonline resource|bcr|2rdacarrier |
---|
500 | |aCover title. |
---|
500 | |a"Date adopted: 2019/05/03; effective date: 2019/05/03; administrative changes date: 2019/06/19." |
---|
500 | |aIssued also in French under title: Ligne directrice : exigences réglementaires associées à une identification numérique attribuée à une drogue (DIN). |
---|
520 | |a"When Health Canada authorizes a drug to be marketed in Canada, a Drug Identification Number (DIN) is issued to the manufacturer and printed on the package labels. A DIN indicates that the evaluation of the drug determined that it met the relevant requirements of the Food and Drugs Act and its regulations and the drug has a favourable risk/benefit profile. Manufacturers of prescription and non‐prescription drugs must obtain a DIN before they are marketed in Canada. Market authorization of a drug may require the additional issuance of a Notice of Compliance (NOC)"--Introduction, page 8. |
---|
650 | 0|aDrugs|xLabeling|zCanada. |
---|
710 | 1 |aCanada. |bHealth Canada. |
---|
775 | 08|tLigne directrice : |w(CaOODSP)9.874556 |
---|
794 | |tGuidance document : |b[2021/06/28 edition]|w(CaOODSP)9.899686 |
---|
795 | |tGuidance document : |b[2019/05/03 edition]|w9.870481 |
---|
856 | 40|qPDF|s307 KB|uhttps://publications.gc.ca/collections/collection_2019/sc-hc/H164-273-2019-1-eng.pdf |
---|